Translate page

 

David Ross Devendra Hiwase Michael Osborn                    

Session 4: CML related topics
Chair: Dr David Ross

  • Myelofibrosis Management
    (Dr David Ross)
  • MPN/MDS Overlap Syndrome
    (Dr David Ross)
  • Pediatric CML
    (Dr Michael Osborn)

 

 

IMG 9703 John Reynolds

David Ross Timothy Hughes                    

Session 5: The CML frontier
Chair: Prof Timothy Hughes

  • Biostats primer for CML clinicians
    (A/Prof John Reynolds)
  • TFR trial update
    (Dr David Ross)
  • Making TFR mainstream
    (Prof Timothy Hughes)

 

Presentations from the 24rd Congress of EHA 

We are pleased to make available a couple of presentations on various aspects of CML management that were first presented at the 24rd Congress of the European Hematology Association in Amsterdam. Presentations include; CML treatment in the era of operational cure: considerations for therapy selection; current treatment approaches in CML, The future of CML therapy: unmet medical needs and new treatments in development, TKI safety and special aspects in children. 

 

Saglio EHA 2019 CML Treatment in the Era of Operational Cure: Considerations for Therapy Selection
Professor Giuseppe Saglio, University of Turin, Italy
 
  • Clinical case: Women, 39 years old including;
    • Considerations for prognosis
    • Considerations on the possibility of TFR
  • ENESTnd study - 5 year update including cumulative incidence of MR4.5
  • Nilotinib is the only TKI registered for discontinuation
  • Summary of Steering Group recommendations derived from patient-physician discussion
  • Conclusion 

This talk was first presented at EHA during the Satellite Symposium: 'Optimizing patient outcomes in CML and classical MPN's: New treatment paradigms and future developments' - supported by Incyte. You will find more education materials from EHA at the EHA Learning Centre

Rosti EHA 2019


Current Treatment Approaches in CML
Professor Gianantonio Rosti, University of Bologna, Italy 

  • The natural course of CML
  • A conceptional model for progression for CML
  • The weight of the choice of 1st line treatment:
    2014 vs. 2019
  • Finding the track for 1st line TKI
    • Reaching earlier milestones of response
    • The disease risk
    • Is the patient 'eligible' for treatment discontinuation?
  • Facing a treatment failure
  • Take home messages

 

 

 

This talk was first presented during the Education Session on Chronic Myeloid Leukemia at EHA. You will find more education materials from EHA at the EHA Learning Centre

Michael Mauro EHA 2019

 

The Future of CML Therapy: Unmet Medical Needs and New Treatments in Development
Professor Michael Mauro, Memorial Sloan Kettering Cancer Center New York, USA 

  • Unmet needs in CML: TKI and SCT
  • TKI's in development for CML
  • Development of Asciminib for CML
  • ABL 001X2101: A multicenter, phase 1, first-in-human study
    •  Allosteric inhibition of BCR-ABL
    •  ABL 001X2201: T315l cohort
    • Asciminib phase 3 study Design NCT 03106779
    • Asciminib Phase 2 study design:
      Add-on to first-line imatinib for DMR NCT 03578367
  • PF-114: 3rd generation BCR-ABL
 

This talk was first presented at EHA during the Satellite Symposium: 'Optimizing patient outcomes in CML and classical MPN's: New treatment paradigms and future developments' - supported by Incyte. You will find more education materials from EHA at the EHA Learning Centre